A

Aquestive Therapeutics Inc
NASDAQ:AQST

Watchlist Manager
Aquestive Therapeutics Inc
NASDAQ:AQST
Watchlist
Price: 2.925 USD 2.99% Market Closed
Market Cap: 289.2m USD

Aquestive Therapeutics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aquestive Therapeutics Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
A
Aquestive Therapeutics Inc
NASDAQ:AQST
Revenue
$57.6m
CAGR 3-Years
4%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Revenue
$89.3B
CAGR 3-Years
4%
CAGR 5-Years
2%
CAGR 10-Years
2%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$47.6B
CAGR 3-Years
0%
CAGR 5-Years
9%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$63.6B
CAGR 3-Years
-8%
CAGR 5-Years
9%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Revenue
$63.9B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
4%
Eli Lilly and Co
NYSE:LLY
Revenue
$45B
CAGR 3-Years
17%
CAGR 5-Years
15%
CAGR 10-Years
9%

Aquestive Therapeutics Inc
Glance View

Market Cap
267.4m USD
Industry
Pharmaceuticals

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 157 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered products to deliver molecules, providing alternatives to care therapies. The company is engaged in advancing a late-stage product pipeline focused on treating diseases of the central nervous system (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. The firm's CNS portfolio, which is focused on epilepsy includes Sympazan and Libervant. The active programs in its complex molecule pipeline portfolio are: AQST-109-SF, AQST-108-SF, and AQST-108-SF. Its PharmFilm technology develops medicines that offer non-invasive delivery, customized suitability for patients with dysphagia, or trouble swallowing, can be administered without water and ensures consistent therapeutic dosing. PharmFilm is comprised of polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs) and excipients in place.

AQST Intrinsic Value
2.447 USD
Overvaluation 16%
Intrinsic Value
Price
A

See Also

What is Aquestive Therapeutics Inc's Revenue?
Revenue
57.6m USD

Based on the financial report for Dec 31, 2024, Aquestive Therapeutics Inc's Revenue amounts to 57.6m USD.

What is Aquestive Therapeutics Inc's Revenue growth rate?
Revenue CAGR 5Y
2%

Over the last year, the Revenue growth was 14%. The average annual Revenue growth rates for Aquestive Therapeutics Inc have been 4% over the past three years , 2% over the past five years .

Back to Top